Research Center: DM Clinical Research
Location: 13406 Medical Complex Dr Suite 190, Tomball, Texas, 77375, United States
Lead Doctor: Muhammad Irfan, MD

Background

Migraines are common and affect about 15% of the adult population. To date, the common treatment for migraines (Triptans) has shown to be not as effective. People have reported inconsistent pain relief and migraine recurrence. In addition, individuals with heart problems on top of migraines cannot take Triptans because it causes narrowing of the blood vessels which might trigger heart issues. 

Researchers are investigating the effectiveness of a new potential option for the acute treatment of migraine attacks. The investigational medication is to be administered through a nasal spray. This new approach also aims to avoid triggering heart problem issues.

The study is seeking adults 18 years old and older. Interested participants must be suffering from moderate to severe migraines. 

Why Participate? 

• You may be able to try a new potential option that may improve migraine symptoms.
• You may experience potential pain relief from migraines. 
• You will receive up to $50 for every study visit completion and additional up to $25 if diary compliance criteria is met on a monthly basis.   
• You may help others suffering from migraines through contributing valuable information.
• You will be helping to advance medical research.

Your Rights

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

• Adults aged 18 years old and older who are experiencing moderate to severe migraines. 
• Must be suffering from migraines for a year or more.
• Able to attend all study visits at the research site on a monthly basis.

Please note:

Due to the current situation with COVID-19 pandemic, the study team would like to point out the following:

• The research site does not treat COVID-19 patients and/or suspected COVID-19 patients.
• The research site’s waiting area is spacious enough that participants will not be within close proximity to each other.
• Hand sanitizers are available at the research site.
• The research staff adheres to strict hygienic practices as well as other safety measures to prevent the spread of COVID-19. 
• Any staff suspected to have COVID-19, or has come into contact with someone who has COVID-19, will automatically undergo a voluntary quarantine for 14 days.
• Interested participants will not be left waiting for a long period of time and will be quickly attended to. 
• Parking is available at the research site.
• The study team encourages the use of personal vehicles, taxi or rideshare services rather than public transit. 
• The research site/institution is taking all precautionary measures to ensure the safety of the study participants.